PHILADELPHIA ORGANIC CHEMISTS' CLUB

DATE: **Thursday, January 26th, 2006; 6:00 pm dinner, 8:00 pm seminar**

PLACE: **Carolyn Hoff Lynch Room, located on the 1st floor (around the corner from the business office), New Chemistry Building, University of Pennsylvania, 34th and Spruce Streets, Philadelphia, PA**

SPEAKER: **Dr. Ron Magolda Vice President of Medicinal Chemistry, Wyeth.**

BIOGRAPHY: Ron Magolda was educated in the Philadelphia area; he attended Villanova University where he was one of the first graduates to receive in 1976 two scientific degrees, a B.S. in Chemistry and a B.S. in General Science. He attended graduate school at the University of Pennsylvania, where he was one of Prof. K. C. Nicolaou's first graduate students. After receiving his PhD in organic chemistry in 1980, Ron joined the Bioorganic Chemistry group in the Central Research Department at the DuPont Company. He later moved to DuPont's Medical Products Department and later DuPont Merck where he rose to the level of Sr. Director and headed the therapeutic area of Inflammatory Research. In 1998, he joined Boehringer-Ingelheim Pharmaceuticals in Ridgefield CT as the Director of Chemistry, where he headed a chemistry department that included synthesis (medicinal chemistry, combichem) along with technology groups of structural research (e.g. protein crystallography), analytical chemistry and screening sciences (e.g. ultra-HTS). Joining Wyeth as Vice President of Medicinal Chemistry in 2002, Ron Magolda now heads two Discovery Medicinal Chemistry groups located at Wyeth's sites in Princeton and Collegeville.

TITLE: ***Design and Synthesis of Selective Estrogen Receptor β Agonists: A Chemical Genomics Approach.***

DINNER: The meeting will be preceded by cocktails (cash bar) at 5:30 pm followed by a dinner at 6:00 pm at La Terrasse 3432 Sansom St. Phila, 19104. Reservations should be made by email: emichelotti@locuspharma.com or phone: (215)-358-2026 to Enrique Michelotti **before 5:00 pm, Monday January 23rd. Please pay the $45.00 for dinner when you attend. Thank you.**

Design and Synthesis of Selective Estrogen Receptor β Agonists: A Chemical Genomics Approach.

Ron Magolda

The discovery of a second subtype of the estrogen receptor (ERβ) in 1996 provided an opportunity to conduct a chemical genomic drug discovery approach. The lack of ER selective agonists tools have prevented characterization of this receptor. Employing a structure-based approach (X-ray crystallography data, molecular modeling) we were able to exploit a single amino acid difference between the two ERs (ERβ Ile_{421} to ERα Met_{373}), and we have designed a series of highly potent and selective agonists for ERβ. We have also characterized their activity in several clinically relevant rodent models. This presentation will describe the design and synthesis of a several highly selective ERβ agonists along with their novel pharmacological profile that offers new insights into the role of ERβ.